Black Diamond Therapeutics (NASDAQ:BDTX) Issues Earnings Results

Black Diamond Therapeutics (NASDAQ:BDTX) announced its earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03, Zacks reports.

Black Diamond Therapeutics Price Performance

Shares of NASDAQ BDTX traded up $0.04 during mid-day trading on Thursday, hitting $1.90. The company’s stock had a trading volume of 196,540 shares, compared to its average volume of 811,365. Black Diamond Therapeutics has a one year low of $1.77 and a one year high of $7.66. The company’s fifty day simple moving average is $2.25 and its 200-day simple moving average is $3.24. The stock has a market cap of $107.51 million, a price-to-earnings ratio of -1.43 and a beta of 2.52.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, November 6th.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.